

References

1. Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. *Lancet Diabetes Endocrinol* 2018;6:392–403
2. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol* 2013;24:302–308
3. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861–869
4. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001;345:851–860
5. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med* 2016;375:323–334
6. Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. *J Am Soc Nephrol* 2017;28:368–375
7. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016;375:1834–1844
8. Perkovic V, Jardine MJ, Neal B, et al.; CREDESCENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;380:2295–2306
9. Bakris GL, Agarwal R, Anker SD, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020;383:2219–2229
10. White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. *J Am Soc Nephrol* 2000;11:1667–1673
11. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. *JAMA* 2002;288:2579–2588
12. Vallon V, Komers R. Pathophysiology of the diabetic kidney. *Compr Physiol* 2011;1:1175–1232
13. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. *Arch Ophthalmol* 1990;108:1234–1244
14. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. *Kidney Int Suppl* 2000;77:S13–S18
15. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. *Diabetes Care* 2005;28:2686–2690
16. Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. *J Am Soc Nephrol* 2017;28:1023–1039
17. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. *Kidney Int* 1996;49:1774–1777
18. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. *Diabetes* 1999;48:2229–2239
19. Gnudi L. Angiopoietins and diabetic nephropathy. *Diabetologia* 2016;59:1616–1620
20. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Müller CA, Müller GA. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. *Pathol Res Pract* 1991;187:251–259
21. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. *Nephrology (Carlton)* 2006;11:226–231
22. Yonemoto S, Machiguchi T, Nomura K, Minakata T, Nanno M, Yoshida H. Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus. *Clin Exp Nephrol* 2006;10:186–192
23. Tesch GH. Macrophages and diabetic nephropathy. *Semin Nephrol* 2010;30:290–301
24. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. *Kidney Int* 2011;79:1051–1060
25. Yu SM, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. *Adv Chronic Kidney Dis* 2018;25:166–180
26. Kinsey GR. Macrophage dynamics in AKI to CKD progression. *J Am Soc Nephrol* 2014;25:209–211
27. Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. *Kidney Int* 2018;93:1344–1355
28. Wang Y, Harris DC. Macrophages in renal disease. *J Am Soc Nephrol* 2011;22:21–27
29. Calle P, Hotter G. Macrophage phenotype and fibrosis in diabetic nephropathy. *Int J Mol Sci* 2020;21:2806
30. Flyvbjerg A. The role of the complement system in diabetic nephropathy. *Nat Rev Nephrol* 2017;13:311–318
31. Østergaard J, Thiel S, Gadjeva M, Hansen TK, Rasch R, Flyvbjerg A. Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. *Diabetologia* 2007;50:1541–1549
32. Hansen TK, Forsblom C, Saraheimo M, et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. *Diabetologia* 2010;53:1517–1524
33. Østergaard JA, Thiel S, Hovind P, et al. Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study. *Diabetologia* 2014;57:2201–2207
34. Falk RJ, Dalmaso AP, Kim Y, et al. Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and immunohistochemical localization in renal disease. *J Clin Invest* 1983;72:560–573
35. Falk RJ, Scheinman JJ, Mauer SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. *Diabetes* 1983;32(Suppl. 2):34–39
36. Falk RJ, Sisson SP, Dalmaso AP, Kim Y, Michael AF, Vernier RL. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. *Am J Kidney Dis* 1987;9:121–128
37. Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. *J Am Soc Nephrol* 2000;11:25–38
38. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. *J Am Soc Nephrol* 2010;21:556–563
39. Perrin NE, Torbjörnsdotter TB, Jaremko GA, Berg UB. Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes. *Pediatr Nephrol* 2004;19:1004–1013
40. Drummond K, Mauer M; International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: II. early renal structural changes in type 1 diabetes. *Diabetes* 2002;51:1580–1587
41. Kim Y, Kleppel MM, Butkowski R, Mauer SM, Wieslander J, Michael AF. Differential expression of basement membrane collagen chains in diabetic nephropathy. *Am J Pathol* 1991;138:413–420
42. Dominguez JH, Tang N, Xu W, et al. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. *Kidney Int* 2000;57:92–104
43. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405–412
44. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving H-H. Progression of nephropathy in type 2 diabetic patients. *Kidney Int* 2004;66:1596–1605
45. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837–853
46. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–1589
47. Curovic VR, Theilade S, Winther SA, et al. Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. *Diabet Med*. Online ahead of print on 11 November 2020 (doi: 10.1111/dme.14459)
48. Hsu CC, Chang HY, Huang MC, et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. *Diabetologia* 2012;55:3163–3172
49. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560–2572

50. Perkovic V, Heerspink HL, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. *Kidney Int* 2013;83:517–523
51. Mann JFE, Ørsted DD, Brown-Frandsen K, et al.; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med* 2017;377:839–848
52. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. *Lancet* 2019;394:131–138
53. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 2020;383:1436–1446
54. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. *J Hypertens* 1993;11:309–317
55. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. *Diabetes* 2006;55:1832–1839
56. Nørgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Deckert T. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1990;33:407–410
57. McMullan CJ, Heerspink HJL, Parving H-H, Dwyer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. *Am J Kidney Dis* 2014;64:714–722
58. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001;345:870–878
59. Persson F, Lindhardt M, Rossing P, Parving H-H. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review. *J Renin Angiotensin Aldosterone Syst* 2016;17:1470320316652047
60. Peti-Peterdi J. High glucose and renin release: the role of succinate and GPR91. *Kidney Int* 2010;78:1214–1217
61. Fridomdt-Møller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. *Curr Opin Nephrol Hypertens* 2020;29:145–151
62. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. *Ann Intern Med* 2006;144:21–28
63. Krikken JA, Bakker SJ, Navis GJ. Role of renal haemodynamics in the renal risks of overweight. *Nephrol Dial Transplant* 2009;24:1708–1711
64. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. *Kidney Int* 2009;76:145–148
65. Bjornstad P, Nehus E, Jenkins T, et al. Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes. *Kidney Int* 2020;97:995–1005
66. Scirica BM, Bohula EA, Dwyer JP, et al.; CAMELLIA-TIMI 61 Steering Committee and Investigators. Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial. *Circulation* 2019;139:366–375
67. von Scholten BJ, Persson F, Svane MS, Hansen TW, Madsbad S, Rossing P. Effect of large weight reductions on measured and estimated kidney function. *BMC Nephrol* 2017;18:52
68. Daousi C, Bain SC, Barnett AH, Gill GV. Hypertriglyceridaemia is associated with an increased likelihood of albuminuria in extreme duration (> 50 years) type 1 diabetes. *Diabet Med* 2008;25:1234–1236
69. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Progression of diabetic nephropathy. *Kidney Int* 2001;59:702–709
70. Thomas MC, Rosengard-Barlund M, Mills V, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. *Diabetes Care* 2006;29:317–322
71. Tolonen N, Forsblom C, Thorn L, et al.; FinnDiane Study Group. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. *Diabetologia* 2008;51:12–20
72. Tofte N, Suviataival T, Ahonen L, et al. Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. *Sci Rep* 2019;9:16398
73. Hsu CC, Chang HY, Huang MC, et al. Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study. *Diabetes Care* 2011;34:982–987
74. Thorn LM, Forsblom C, Waden J, et al.; Finnish Diabetic Nephropathy (FinnDiane) Study Group. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. *Diabetes Care* 2009;32:950–952
75. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. *Diabetes Care* 2007;30:707–712
76. Metascreen Writing Committee; Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. *Diabetes Care* 2006;29:2701–2707
77. Oellgaard J, Gaede P, Rossing P, Persson F, Parving H-H, Pedersen O. Intensified multifactorial intervention in type 2 diabetes with microalbuminuria leads to long-term renal benefits. *Kidney Int* 2017;91:982–988
78. Sandholm N, Van Zuydam N, Ahlqvist E, et al.; The FinnDiane Study Group; Tuomilehto J, Lyssenko V, McKeigue PM, et al.; The DCCT/EDIC Study Group; Florez JC, Hirschhorn JN, Maxwell AP, GENIE Consortium; Dunger D, Cobelli C, Colhoun HM, et al.; SUMMIT Consortium. The genetic landscape of renal complications in type 1 diabetes. *J Am Soc Nephrol* 2017;28:557–574
79. van Zuydam NR, Ahlqvist E, Sandholm N, et al. A genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes. *Diabetes* 2018;67:1414–1427
80. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy. *N Engl J Med* 1989;320:1161–1165
81. Imperatore G, Nelson RG. Genetic susceptibility to nephropathy in Pima Indians with type 2 diabetes mellitus. *Nephrology* 1998;4(Suppl. 2):S34–S39
82. Fagerudd JA, Tarnow L, Jacobsen P, et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. *Diabetes* 1998;47:439–444
83. Thorn LM, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Kilpikari R, Groop P-H; FinnDiane Study Group. Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. *Diabetes Care* 2007;30:1162–1167
84. Wuttke M, Li Y, Li M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nat Genet* 2019;51:957–972
85. Keating ST, van Diepen JA, Riksen NP, El-Osta A. Epigenetics in diabetic nephropathy, immunity and metabolism. *Diabetologia* 2018;61:6–20
86. Allawi J, Rao PV, Gilbert R, et al. Microalbuminuria in non-insulin-dependent diabetes: its prevalence in Indian compared with European patients. *Br Med J (Clin Res Ed)* 1988;296:462–464
87. Dreyer G, Hull S, Aitken Z, Chesser A, Yaqoob MM. The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. *QJM* 2009;102:261–269
88. Sinha SK, Shaheen M, Rajavashisth TB, Pan D, Norris KC, Nicholas SB. Association of race/ethnicity, inflammation, and albuminuria in patients with diabetes and early chronic kidney disease. *Diabetes Care* 2014;37:1060–1068
89. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. *Diabetes Care* 1995;18:182–187
90. Joshy G, Dunn P, Fisher M, Lawrenson R. Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission rate for renal complications, and incidence of end-stage renal disease and renal death. *Diabetologia* 2009;52:1474–1478
91. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane AW. Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru. *Diabetes* 1989;38:1602–1610
92. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care* 2013;36:1735–1741
93. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. *Diabetes Care* 2012;35:1265–1271
94. Dyck RF, Jiang Y, Osgood ND. The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes. *Can J Diabetes* 2014;38:237–243
95. Chan JC, Lau ES, Luk AO, et al. Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis. *Am J Med* 2014;127:616–624
96. Sellers EA, Blydt-Hansen TD, Dean HJ, Gibson IW, Birk PE, Ogborn M. Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes. *Diabetes Care* 2009;32:786–790
97. Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. *Diabet Med* 2007;24:1136–1142

98. Rossing P, Hougaard P, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. *Diabetes Care* 2002;25:859–864
99. de Zeeuw D, Ramjit D, Zhang Z, et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. *Kidney Int* 2006;69:1675–1682
100. Babazono T, Nyumura I, Toya K, et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. *Diabetes Care* 2009;32:1518–1520
101. Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. *Clin J Am Soc Nephrol* 2012;7:401–408
102. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. *Diabetologia* 1994;37:511–516
103. Heerspink HJL, Greene T, Tighiouart H, et al.; Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol* 2019;7:128–139
104. Gordin D, Hiilesmaa V, Fagerudd J, et al.; FinnDiane Study Group. Pre-eclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women. *Diabetologia* 2007;50:516–522
105. Shultis WA, Weil EJ, Looker HC, et al. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. *Diabetes Care* 2007;30:306–311
106. Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic nephropathy: a cohort study. *Diabetes Care* 2013;36:3718–3725
107. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. *Diabetologia* 2008;51:444–450
108. Targher G, Mantovani A, Picchiri I, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. *Diabetes Care* 2014;37:1729–1736
109. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013;3:1–150
110. Rossing P, Persson F, Fridomt-Moller M, Hansen TW. Linking kidney and cardiovascular complications in diabetes: impact on prognostication and treatment: the 2019 Edwin Bierman Award Lecture. *Diabetes* 2021;70:39–50
111. de Zeeuw D, Remuzzi G, Parving H-H, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 2004;110:921–927
112. Coresh J, Heerspink HJL, Sang Y, et al.; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. *Lancet Diabetes Endocrinol* 2019;7:115–127
113. Desai AS, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. *Am J Kidney Dis* 2011;58:717–728
114. Galsgaard J, Persson F, Hansen TW, et al. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. *Kidney Int* 2017;92:1242–1248
115. Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. *Mol Cell Proteomics* 2010;9:2424–2437
116. Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. *Diabetes* 2012;61:3304–3313
117. Tofte N, Lindhardt M, Adamova K, et al.; PRIORITY Investigators. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. *Lancet Diabetes Endocrinol* 2020;8:301–312
118. Amdur RL, Feldman HI, Gupta J, et al.; CRIC Study Investigators. Inflammation and progression of CKD: the CRIC study. *Clin J Am Soc Nephrol* 2016;11:1546–1556
119. Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. *Nat Med* 2019;25:805–813
120. Pilemann-Lyberg S, Hansen TW, Tofte N, et al. Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes. *Diabetes Care* 2019;42:1088–1094
121. Doria A, Galecki AT, Spino C, et al.; PERL Study Group. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. *N Engl J Med* 2020;382:2493–2503
122. Ahola AJ, Sandholm N, Forsblom C, Harjutsalo V, Dahlstrom E, Groop P-H; FinnDiane Study Group. The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes. *Kidney Int* 2017;91:1178–1185
123. Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. *Am J Kidney Dis* 2021;77:481–489
124. Kjaer LK, Cejvanovic V, Henriksen T, et al. Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoGuo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study. *Diabetes Care* 2017;40:1771–1778
125. Komorowski CV, Brosius FC III, Pennathur S, Kretzler M. Perspectives on systems biology applications in diabetic kidney disease. *J Cardiovasc Transl Res* 2012;5:491–508
126. Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. *Diabetologia* 2016;59:1624–1627
127. Pena MJ, Heerspink HJL, Hellemons ME, et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus. *Diabet Med* 2014;31:1138–1147
128. Solini A, Manca ML, Penno G, Pugliese G, Cobb JE, Ferrannini E. Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics. *J Clin Endocrinol Metab* 2016;101:696–704
129. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. *J Am Soc Nephrol* 2013;24:1901–1912
130. Niewczas MA, Sirich TL, Mathew AV, et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. *Kidney Int* 2014;85:1214–1224
131. Tofte N, Suvitaival T, Trost K, et al. Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes. *Front Endocrinol (Lausanne)* 2019;10:818
132. Parving H-H, Mauer M, Fioretto P, Rossing P, Ritz E. Diabetic nephropathy. In *Brenner and Rector's the Kidney*. 9th ed. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, Eds. Philadelphia, PA, Elsevier, 2012, p. 1411–1454
133. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. *N Engl J Med* 2003;348:2285–2293
134. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. *BMJ* 2004;328:1105
135. Gaede P, Tarnow L, Vedel P, Parving H-H, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. *Nephrol Dial Transplant* 2004;19:2784–2788
136. Solini A, Penno G, Bonora E, et al.; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study 2012;35:143–149
137. Critselis E, Vlahou A, Stel VS, Morton RL. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. *Nephrol Dial Transplant* 2018;33:441–449
138. Tuttle KR, Alicic RZ, Duru OK, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. *JAMA Netw Open* 2019;2:e1918169
139. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes: global burden of disease and forecasted trends. *J Epidemiol Glob Health* 2020;10:107–111
140. Whaley-Connell A, Sowers JR. Basic science: pathophysiology: the cardiorenal metabolic syndrome. *J Am Soc Hypertens* 2014;8:604–606
141. Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. *Diabetes Obes Metab* 2018;20:2000–2003

142. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. *J Am Coll Cardiol* 2008;52:1527–1539
143. Dokken BB. The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. *Diabetes Spectr* 2008;21:160–165
144. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. *JAMA* 1979;241:2035–2038
145. Gore MO, Patel MJ, Kosiborod M, et al.; National Registry of Myocardial Infarction Investigators. Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006. *Circ Cardiovasc Qual Outcomes* 2012;5:791–797
146. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol* 2018;34:575–584
147. Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. *Front Physiol* 2018;9:1669
148. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. *Diabetes Care* 2001;24:1614–1619
149. Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA. Heart failure with preserved ejection fraction in diabetes: mechanisms and management. *Can J Cardiol* 2018;34:632–643
150. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy. *Circ Res* 2018;122:624–638
151. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. *Circ Res* 2019;124:121–141
152. Jensen MT, Fung K, Aung N, et al. Changes in cardiac morphology and function in individuals with diabetes mellitus. *Circ Cardiovasc Imaging* 2019;12:e009476
153. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. *J Nephropharmacol* 2016;5:49–56
154. Piccoli GB, Grassi G, Cabiddu G, et al. Diabetic kidney disease: a syndrome rather than a single disease. *Rev Diabet Stud* 2015;12:87–109
155. Brown JM, Everett BM. Cardioprotective diabetes drugs: what cardiologists need to know. *Cardiovasc Endocrinol Metab* 2019;8:96–105
156. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA Cardiol* 2021;6:148–158
157. American Diabetes Association. 10. Cardiovascular disease and risk management: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care* 2021;44(Suppl. 1):S125–S150
158. Pugliese G, Penno G, Natali A, et al.; Italian Diabetes Society; Italian Society of Nephrology. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function.” *J Nephrol* 2020;33:9–35
159. Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2019;380:347–357
160. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. *Lancet Diabetes Endocrinol* 2019;7:606–617
161. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;377:644–657
162. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2019;7:845–854
- 162a. U.S. Food and Drug Administration. FDA approves treatment for chronic kidney disease: approval is first to cover many causes of disease. Available from <https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease>. Accessed 5 May 2021
163. Pitt B, Pfeffer MA, Assmann SF, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014;370:1383–1392
164. de Denus S, O’Meara E, Desai AS, et al. Spironolactone metabolites in TOPCAT: new insights into regional variation. *N Engl J Med* 2017;376:1690–1692
165. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. *Clin J Am Soc Nephrol* 2017;12:2032–2045
166. Centers for Disease Control and Prevention. *National Diabetes Statistics Report, 2020*. Atlanta, GA, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2020
167. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. *Am J Kidney Dis* 2014;64:510–533
168. American Diabetes Association. 11. Microvascular complications and foot care: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care* 2021;44(Suppl. 1):S151–S167
169. Shlipak MG, Tummalapalli SL, Boulware LE, et al.; Conference Participants. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. *Kidney Int* 2021;99:34–47
170. Nolte E, McKee M. Variations in amenable mortality: trends in 16 high-income nations. *Health Policy* 2011;103:47–52
171. Schroeder SA. Shattuck Lecture. We can do better: improving the health of the American people. *N Engl J Med* 2007;357:1221–1228
172. Hall YN. Social determinants of health: addressing unmet needs in nephrology. *Am J Kidney Dis* 2018;72:582–591
173. Norton JM, Moxey-Mims MM, Eggers PW, et al. Social determinants of racial disparities in CKD. *J Am Soc Nephrol* 2016;27:2576–2595
174. Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. *Adv Chronic Kidney Dis* 2015;22:6–15
175. Bailey ZD, Feldman JM, Bassett MT. How structural racism works: racist policies as a root cause of U.S. racial health inequities. *N Engl J Med* 2021;384:768–773
176. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. *Lancet* 2017;389:1453–1463
177. Moosa MR, Norris KC. Sustainable social development: tackling poverty to achieve kidney health equity. *Nat Rev Nephrol* 2021;17:3–4
178. Laster M, Shen JI, Norris KC. Kidney disease among African Americans: a population perspective. *Am J Kidney Dis* 2018;72(Suppl. 1):S3–S7
179. Crews DC, Pfaff T, Powe NR. Socioeconomic factors and racial disparities in kidney disease outcomes. *Semin Nephrol* 2013;33:468–475
180. Geronimus AT, Hicken M, Keene D, Bound J. “Weathering” and age patterns of allostatic load scores among Blacks and Whites in the United States. *Am J Public Health* 2006;96:826–833
181. Marmot M, Friel S, Bell R, Houweling TA, Taylor S; Commission on Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. *Lancet* 2008;372:1661–1669
182. Wen M, Browning CR, Cagney KA. Poverty, affluence, and income inequality: neighborhood economic structure and its implications for health. *Soc Sci Med* 2003;57:843–860
183. Payne RK, Blair T. *A Framework for Understanding Poverty*. Highlands, TX, aha! Process, 2005.
184. Duru OK, Middleton T, Tewari MK, Norris K. The Landscape of diabetic kidney disease in the United States. *Curr Diab Rep* 2018;18:14
185. De la Fuente F, Saldías MA, Cubillos C, et al. Green space exposure association with type 2 diabetes mellitus, physical activity, and obesity: a systematic review. *Int J Environ Res Public Health* 2020;18:97
186. Eberly LA, Yang L, Eneanya ND, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. *JAMA Netw Open* 2021;4:e216139
187. Oppenheimer GM. Paradigm lost: race, ethnicity, and the search for a new population taxonomy. *Am J Public Health* 2001;91:1049–1055
188. Genovese G, Friedman DJ, Ross, MD, et al. Association of trypanolytic APOL1 variants with kidney disease in African Americans. *Science* 2010;329:841–845
189. Umeukeje EM, Young BA. Genetics and ESKD disparities in African Americans. *Am J Kidney Dis* 2019;74:811–821
190. Gutiérrez OM, Irvin MR, Chaudhary NS, et al. APOL1 nephropathy risk variants and incident cardiovascular disease events in community-dwelling Black adults. *Circ Genom Precis Med* 2018;11:e002098
191. Palmer ND, Freedman BI. APOL1 and progression of nondiabetic nephropathy. *J Am Soc Nephrol* 2013;24:1344–1346
192. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461–470
193. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–612

194. Norris KC, Eneanya ND, Boulware LE. Removal of race from estimates of kidney function: first, do no harm. *JAMA* 2021;325:135–137
195. Subramanian SV, Jones K, Kaddour A, Krieger N. Revisiting Robinson: the perils of individualistic and ecologic fallacy. *Int J Epidemiol* 2009;38:342–360; author reply 370–373
196. American Diabetes Association. 1. Improving care and promoting health in populations: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care* 2021;44(Suppl. 1):S7–S14
197. Pagels AA, Hylander B, Alvarsson M. A multi-dimensional support programme for patients with diabetic kidney disease. *J Ren Care* 2015;41:187–194
198. Tuot DS, Diamantidis CJ, Corbett CF, et al. The last mile: translational research to improve CKD outcomes. *Clin J Am Soc Nephrol* 2014;9:1802–1805
199. Narva AS, Norton JM, Boulware LE. Educating patients about CKD: the path to self-management and patient-centered care. *Clin J Am Soc Nephrol* 2016;11:694–703
200. Goldstein K, Briggs M, Oleynik V, et al. Using digital media to promote kidney disease education. *Adv Chronic Kidney Dis* 2013;20:364–369
201. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. *Diabetes Care* 2014;37:2864–2883
202. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. *JAMA* 2016;316:602–610
203. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA* 2011;305:2532–2539
204. de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. *Diabetes Care* 2014;37:24–30
205. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. *Exp Biol Med* (Maywood) 2016;241:1323–1331
206. Plantinga LC, Crews DC, Coresh J, et al.; CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. *Clin J Am Soc Nephrol* 2010;5:673–682
207. United States Renal Data System. *Annual Data Report: Epidemiology of Kidney Disease in the United States*. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2016
208. Fox CS, Matsushita K, Woodward M, et al.; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* 2012;380:1662–1673
209. Groop P-H, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes* 2009;58:1651–1658
210. Kramer HJ, Nguyen QD, Curhan G, Hsu C-Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. *JAMA* 2003;289:3273–3277
211. Molitch ME, Steffes M, Sun W, et al.; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. *Diabetes Care* 2010;33:1536–1543
212. Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. Available from <https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html>. Accessed 14 April 2021
213. Hemmelgarn BR, James MT, Manns BJ, et al. Rates of treated and untreated kidney failure in older vs younger adults. *JAMA* 2012;307:2507–2715
214. Wouters OJ, O'Donoghue DJ, Ritchie J, Kanavos PG, Narva AS. Early chronic kidney disease: diagnosis, management and models of care. *Nat Rev Nephrol* 2015;11:491–502
215. Yarnoff BO, Hoerger TJ, Simpson SK, et al.; Centers for Disease Control and Prevention CKD Initiative. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. *BMC Nephrol* 2017;18:85
216. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guidelines for diabetes management in chronic kidney disease. *Kidney Int* 2020;98(4 Suppl):S1–S115
217. de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. *Kidney Int* 2020;98:839–848
218. Dagogo-Jack S. Complications of diabetes mellitus. In *Scientific American Medicine*. Singh AK, Ed. Hamilton, Ontario, Canada, Decker Intellectual Properties, 2015
219. Rossing P, Rossing K, Gaede P, Pedersen O, Parving H-H. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. *Diabetes Care* 2006;29:1024–1030
220. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. *Am J Kidney Dis* 2013;62:1095–1101
221. Gomes MB, Gonçalves MF. Is there a physiological variability for albumin excretion rate? Study in patients with diabetes type 1 and nondiabetic individuals. *Clin Chim Acta* 2001;304:117–123
222. Dagogo-Jack S, Egbuonu N, Edeoga C. Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. *Med Princ Pract* 2010;19:167–175
223. Klahr S, Levey AS, Beck GJ, et al.; Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. *N Engl J Med* 1994;330:877–884
224. Murray DP, Young L, Waller J, et al. Is dietary protein intake predictive of 1-year mortality in dialysis patients? *Am J Med Sci* 2018;356:234–243
225. Mills KT, Chen J, Yang W, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. *JAMA* 2016;315:2200–2210
226. Nilsson E, Gasparini A, Arnlov J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. *Int J Cardiol* 2017;245:277–284
227. Dagogo-Jack S. Glycemic control and chronic diabetes complications. In *Therapy for Diabetes Mellitus and Related Disorders*. 6th ed. Umpierrez GE, Ed. Alexandria, VA, American Diabetes Association, 2014, p. 668–695
228. Writing Team for the DCCT/EDIC Research Group. Sustained effects of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy. *JAMA* 2003;290:2159–2167
229. DCCT/EDIC Research Group; de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 2011;365:2366–2376
230. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. *N Engl J Med* 2008;359:1565–1576
231. Long AN, Dagogo-Jack S. The comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. *J Clin Hypertens* (Greenwich) 2011;13:244–251
232. Dagogo-Jack S. Preventing diabetes-related morbidity and mortality in the primary care setting. *J Natl Med Assoc* 2002;94:549–560
233. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998;317:703–713
234. Leehey DJ, Zhang JH, Emanuele NV, et al.; VA NEPHRON-D Study Group. BP and renal outcomes in diabetic kidney disease: the Veterans Affairs Nephropathy in Diabetes Trial. *Clin J Am Soc Nephrol* 2015;10:2159–2169
235. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1575–1585
236. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 1993;329:1456–1462
237. Fried LF, Emanuele N, Zhang JH, et al.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med* 2013;369:1892–1903
238. Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet* 2015;386:2059–2068
239. Bakris GL, Agarwal R, Chan JC, et al.; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. *JAMA* 2015;314:884–894
240. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. *Clin J Am Soc Nephrol* 2009;4:1121–1127
241. Chu PY, Hackstadt AJ, Chipman J, et al. Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas. *Diabetes Care* 2020;43:1462–1470
242. U.S. Food and Drug Administration. FDA drug safety communication: FDA

- revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available from <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain>. Accessed 11 August 2020
243. Lalau J-D, Kajbaf F, Bennis Y, Hurtel-Lemaire A-S, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. *Diabetes Care* 2018;41:547–553
244. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–986
245. Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. *Curr Atheroscler Rep* 2010;12:432–439
246. Zoungas S, Arima H, Gerstein HC, et al.; Collaborators on Trials of Lowering Glucose (CONTROL) Group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol* 2017;5:431–437
247. Agrawal L, Azad N, Bahn GD, et al.; VADT Study Group. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). *Diabetologia* 2018;61:295–299
248. Zaccardi F, Dhalwani NN, Webb DR, Davies MJ, Khunti K. Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. *Diabetologia* 2018;61:1592–1602
249. Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes: a systematic review. *Cardiovasc Diabetol* 2013;12:135
250. Cherney DZI, Perkins BA, Soleymannou N, et al. Renal hemodynamic effect of sodium glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation* 2014;129:587–597
251. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium–glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. *J Am Coll Cardiol* 2018;72:1845–1855
252. Woods TC, Satou R, Miyata K, et al. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. *Am J Nephrol* 2019;49:331–342
253. Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. *Diabetologia* 2019;62:1154–1166
254. Yarbeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A. Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. *J Cell Physiol* 2018;234:223–230
255. Arjun S, Bell RM. SGLT2 inhibitors: reviving the sodium–hydrogen exchanger cardioprotection hypothesis? *Cardiovasc Res* 2019;115:1454–1456
256. Jardine MJ, Mahaffey KW, Neal B, et al.; CREDENCE Study Investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. *Am J Nephrol* 2017;46:462–472
257. Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;383:1413–1424
258. Boehringer Ingelheim. Invokana (canagliflozin) prescribing information, 2020. Available from <https://docs.boehringer-ingelheim.com/Prescribing%20Information/Pls/Jardiance/jardiance.pdf>. Accessed 10 March 2021
259. AstraZeneca. Farxiga (dapagliflozin) prescribing information, 2020. Available from https://den8dha6z50e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition_v.pdf. Accessed 10 March 2021
260. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. *Diabetes Metab Syndr Obes* 2013;6:453–467
261. Merck. Steglatro (ertugliflozin) prescribing information. Available from https://www.merck.com/product/usa/pi_circulars/s/steglatro/steglatro_pi.pdf. Accessed 10 March 2021
262. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. *Circulation* 2019;139:2022–2031
263. [ClinicalTrials.gov](https://clinicaltrials.gov). A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). Available from <https://clinicaltrials.gov/ct2/show/NCT03819153>. Accessed 10 March 2021
264. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? *Arch Intern Med* 2000;160:685–693
265. Collard D, Brouwer TF, Peters RJG, Vogt L, van den Born BH. Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus. *Hypertension* 2018;72:1337–1344
266. James MT, Grams ME, Woodward M, et al.; CKD Prognosis Consortium. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. *Am J Kidney Dis* 2015;66:602–612
267. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. *Clin J Am Soc Nephrol* 2011;6:2567–2572
268. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD; National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Practical approach to detection and management of chronic kidney disease for the primary care clinician. *Am J Med* 2016;129:153–162.e7
269. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract* 2014;103:137–149
270. International Diabetes Federation. *Diabetes Atlas*. 9th ed. Brussels, Belgium, International Diabetes Federation, 2019
271. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet* 2015;385:1975–1982
272. Levin A, Tonelli M, Bonventre J, et al.; ISN Global Kidney Health Summit Participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet* 2017;390:1888–1917
273. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. *Diabetes Care* 2014;37:867–875
274. Patel RB, Colangelo LA, Reis JP, et al. Association of longitudinal trajectory of albuminuria in young adulthood with myocardial structure and function in later life: Coronary Artery Risk Development in Young Adults (CARDIA) study. *JAMA Cardiol* 2020;5:184–192
275. Bakris GL, Weir MR, Shanifar S, et al.; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. *Arch Intern Med* 2003;163:1555–1565
276. Viberti G, Wheeldon NM; Microalbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 2002;106:672–678
277. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care* 2021;44(Suppl. 1):S111–S124
278. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. *BMJ* 1994;309:833–837
279. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. *Kidney Int* 1996;50:1641–1650
280. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. *Hypertension* 1997;29:744–750
281. Bakris G, Oshima M, Mahaffey KW, et al. Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m²: subgroup analysis of the randomized CREDENCE trial. *Clin J Am Soc Nephrol* 2020;15:1705–1714
282. Mann JFE, Green D, Jamerson K, et al.; ASCEND Study Group. Avoentan for overt diabetic nephropathy. *J Am Soc Nephrol* 2010;21:527–535
283. Packham DK, Wolfe R, Reutens AT, et al.; Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. *J Am Soc Nephrol* 2012;23:123–130
284. Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW; PKC-DRS, PKC-DRS 2 Study Groups. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. *Clin J Am Soc Nephrol*, 2007;2:631–636
285. Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. *J Am Soc Nephrol* 2011;22:1144–1151
286. Parving H-H, Brenner BM, McMurray JVV, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med* 2012;367:2204–2213
287. de Zeeuw D, Akizawa T, Audhya P, et al.; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N Engl*

288. ONTARGET Investigators; Yusef S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008; 358:1547–1559
289. Bakris GL. Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors. *Am J Kidney Dis* 2019;74:573–575
290. Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. *Kidney Int* 2021;99:750–762
291. Oshima M, Jardine MJ, Agarwal R, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. *Kidney Int* 2021;99:999–1009
292. Dekkers CCJ, Wheeler DC, Sjöström CD, Stefánsson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. *Nephrol Dial Transplant* 2018;33:2005–2011
293. Sternlicht H, Bakris GL. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. *Curr Hypertens Rep* 2019;21:12
294. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. *J Am Coll Cardiol* 2020;75:422–434
295. Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. *Hypertension* 2020;75:894–901
296. Packer M. Mitigation of the adverse consequences of nutrient excess on the kidney: a unified hypothesis to explain the renoprotective effects of sodium-glucose cotransporter 2 inhibitors. *Am J Nephrol* 2020;51:289–293
297. Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. *JACC Basic Transl Sci* 2020;5:169–179
298. Heerspink HHJ, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. *Circulation* 2016;134:752–772
299. Jardine MJ, Zhou Z, Mchaffey KW, et al.; CREDENCE Study Investigators. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. *J Am Soc Nephrol* 2020;31:1128–1139
300. Mayer GJ, Wanner C, Weir MR, et al. Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. *Kidney Int* 2019;96:489–504
301. Mahaffey KW, Neal B, Perkovic V, et al.; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). *Circulation* 2018;137:323–334
302. Cannon CP, Pratley R, Dagogo-Jack S, et al.; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med* 2020;383:1425–1435
303. Wheeler DC, Stefánsson BV, Jongs N, et al.; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes Endocrinol* 2021;9:22–31
304. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 2006;368:1696–1705
305. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. *Lancet Diabetes Endocrinol* 2018;6:605–617
306. Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. *Kidney Int* 2021;99:314–318
307. Qiu M, Ding L-L, Wei X-B, Liu S-Y, Zhou H-R. Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis. *J Cardiovasc Pharmacol* 2021;77:34–37
308. Verma S, McGuire DK, Bain SC, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. *Diabetes Obes Metab* 2020;22:2487–2492
309. Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. *Diabetes Ther* 2020;11:835–844
310. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;375:311–322
311. Holman RR, Bethel MA, Hernandez AF. Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2017;377:2502
312. [ClinicalTrials.gov](https://clinicaltrials.gov). Renal effects of treatment with empagliflozin alone or in combination with semaglutide in patients with type 2 diabetes and albuminuria (EmpaSema). Available from <https://clinicaltrials.gov/ct2/show/NCT04061200>. Accessed 5 March 2021
313. Hermidorff MM, de Assis LVM, Isoldi MC. Genomic and rapid effects of aldosterone: what we know and do not know thus far. *Heart Fail Rev* 2017;22:65–89
314. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* 2003;41:64–68
315. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. *Eur Heart J* 2021;42:152–161
316. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. *Clin J Am Soc Nephrol* 2006;1:940–951
317. Al Dhaybi O, Bakris GL. Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease. *Diabetes Obes Metab* 2020;22(Suppl. 1):69–76
318. Ruilope LM, Agarwal R, Anker SD, et al.; FIGARO-DKD Study Investigators. Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial. *Am J Nephrol* 2019;50:345–356
319. Filippatos G, Anker SD, Agarwal R, et al.; FIDELIO-DKD Investigators. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. *Circulation* 2021;143:540–552
320. Heerspink HJL, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. *Kidney Int* 2021;99:346–349
321. Zhao Y, Vanhoutte PM, Leung SWS. Vascular nitric oxide: beyond eNOS. *J Pharmacol Sci* 2015;129:83–94